Project Grant R21AA032088
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...
- This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
- This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs), supports research to determine the molecular mechanism by which the neutrophilic NCF1 gene and its downstream target miR-223 impact the pathogenesis of alcohol-associated liver disease (ALD). The $249,000 project, awarded to the Trustees of Indiana University, will investigate how neutrophils drive disease severity and mediate liver injury in ALD through the...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $249,000.00 to East Tennessee State University to characterize acetaldehyde-protein adducts and their effects on lymphocyte function in alcohol-associated liver disease. The research aims to investigate how the ethanol metabolite acetaldehyde forms adducts on proteins, particularly albumin, and how this modulates the pathogenesis of...
- This federal Project Grant award of $659,865 from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) supports research at Yale University to investigate the role of aberrant mitochondrial calcium signaling in the development of alcohol-associated hepatitis (AAH). The project will examine how the expression and localization of the inositol trisphosphate receptor (ITPR) isoforms, particularly ITPR3, impact mitochondrial calcium signals and cellular...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,376,398 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to develop a humanized mouse model to study alcohol-associated hepatitis (AAH). The project aims to create a fully humanized mouse liver system by engrafting human hepatocytes and non-parenchymal cells to better understand the complex cell interactions that drive key features of AAH, a leading cause of liver-related deaths...
- This $202,176 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 Alcohol Research Programs) aims to develop novel machine learning tools and spatial transcriptomic approaches to accurately diagnose and predict the severity of alcohol-associated liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), and the emerging mixed-etiology disease metabolic syndrome-associated alcoholic liver disease (METALD). The grant recipient,...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) provides $3,168,729 to New York University to conduct a collaborative research project titled "A Translational Approach for Novel Precision Medicine Models." The project aims to identify novel molecular targets and mechanisms of treatment responses in alcohol use disorder (AUD) based on the role of mitochondrial metabolism and epigenetic...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $404,250 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center. The grant, awarded on September 23, 2025 with an ultimate completion date of August 31, 2027, supports research to explore the role of margaric acid in alcohol-associated liver diseases (AALD). The project aims to determine if margaric acid supplementation can attenuate alcohol-induced gut and liver...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology and human hepatocytes to study protein interactions, and plans to assess the effectiveness of two formulations to treat ALD: GalNAc-siRNA-METTL7A conjugates to inhibit METTL7A, and AAV7-HMETTL7A-S53A to deactivate METTL7A phosphorylation. The project will run from September 16, 2025 to August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $440.6k | 9/16/25 |